Page 98 - Sohini Das

We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

FabiFlu cheaper than other drugs to treat Covid-19, claims Glenmark

The company further claimed that since favipiravir was an oral therapy, patients could be treated on an out-patient basis without incurring additional hospitalisation expenses

Covid-19 treatment: A lowdown on possible cure and drugs being used

Business Standard takes a look at the common drugs that are being used in India for treating Covid-19 patients

Glenmark under fire for over pricing, 'misguided' claims of Covid-19 drug

NCP legislator Amol Kolhe's letter to Health Minister Harsh Vardhan triggers the DCGI to seek details from the Mumbai-based drugmaker

Covid-19: Vaccine firms give Moderna a shrug, say no rush on tie-ups

Most players that Business Standard spoke to said they would be concentrating on their own vaccine candidates or the current tie-ups that they have

India to launch Covid-19 vaccine by August 15: ICMR chief Bhargava

ICMR and Hyderabad-based Bharat Biotech are jointly working on preclinical as well as clinical development of Covaxin

Covid-19 crisis: Race to develop vaccine gets a booster as field widens

On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.

GI Council wants standard Covid treatment rates for easier claim settlement

Insurers will be guided by referral rates while processing hospitalisation claims. If actual charges exceed referral rates due to various medical exigencies, insurers will consider them while processi

KKR to acquire controlling stake in JB Chemicals for Rs 3,750 crore

The total deal size thus will be around $500 mn or around Rs 3,750 crore

More drugs may see price revisions as raw material costs, expenses rise

API prices have gone up by 25-30 per cent for some drugs in recent months

As cases rise, surge in bio-waste raises a fresh challenge in Covid fight

Used protective gear, masks, gloves and syringes add to environmental concerns as well as financial costs of hospitals

Policy flip-flops may puncture India's image as 'pharmacy of the world'

India supplies almost 20 per cent of the medicines consumed by the world. Every third tablet in the US market is from India

DRL to launch innovator brand of favipiravir, is silent on pricing

Ties up with Fujifilm for exclusive rights over Avigan for Indian market, can sell overseas too

China crisis, India scouting for APIs a shot in arm for sick pharma PSU

Govt is trying to reduce dependence on China for APIs and develop indigenous sources

Relief for pharma firms as govt starts clearing API imports from China

This comes after a week of economic disruption caused by introducing stringent scrutiny, resulting in shipments originating in China getting held up at Indian ports.

Covid-19 crisis: Health care workers may get vaccine after phase 2 trials

Indigenously developed Bharat Biotech's vaccine candidate Covaxin is entering human trials on Wednesday.

Covid-19 crisis: Bharat Biotech's vaccine gets nod for human trials

The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred to Bharat Biotech.

Covid-19 crisis: Govt allows PPE exports after prices crash over 65%

Prices of some grades of PPE have crashed by over 65 per cent in the last one and a half months owing to glut in the domestic market.

Mumbai tweaks discharge protocol in bid to free tertiary care beds faster

City's top hospitals say average length of stay for a Covid-19 patient is now around seven days, down 50% from 14-days in the beginning of the pandemic

Sun Pharma to launch its first innovative product for psoriasis in Japan

Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late